IS7750A - Inngjafarform fyrir lyfjafræðilega virk peptíð með samfellda losun og aðferð við framleiðslu þeirra - Google Patents
Inngjafarform fyrir lyfjafræðilega virk peptíð með samfellda losun og aðferð við framleiðslu þeirraInfo
- Publication number
- IS7750A IS7750A IS7750A IS7750A IS7750A IS 7750 A IS7750 A IS 7750A IS 7750 A IS7750 A IS 7750A IS 7750 A IS7750 A IS 7750A IS 7750 A IS7750 A IS 7750A
- Authority
- IS
- Iceland
- Prior art keywords
- administration
- production
- pharmacologically active
- active peptides
- continuous release
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41422502P | 2002-09-27 | 2002-09-27 | |
| DE10245525A DE10245525A1 (de) | 2002-09-27 | 2002-09-27 | Darreichungsform für pharmazeutisch aktive Peptide mit anhaltender Wirkstofffreigabe (sustained release) und Verfahren zu deren Herstellung |
| DE10320051 | 2003-04-26 | ||
| PCT/EP2003/010732 WO2004030650A2 (de) | 2002-09-27 | 2003-09-26 | Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe (sustained release) und verfahren zu deren herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7750A true IS7750A (is) | 2005-03-17 |
Family
ID=43646377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7750A IS7750A (is) | 2002-09-27 | 2005-03-17 | Inngjafarform fyrir lyfjafræðilega virk peptíð með samfellda losun og aðferð við framleiðslu þeirra |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7884071B2 (is) |
| EP (1) | EP1565160B1 (is) |
| JP (1) | JP4898118B2 (is) |
| KR (1) | KR100633280B1 (is) |
| CN (1) | CN100509053C (is) |
| AU (1) | AU2003287950B2 (is) |
| BR (1) | BRPI0314546B8 (is) |
| CA (1) | CA2507524C (is) |
| DK (1) | DK1565160T3 (is) |
| ES (1) | ES2457019T3 (is) |
| HR (1) | HRP20050371B1 (is) |
| IL (1) | IL167415A (is) |
| IS (1) | IS7750A (is) |
| ME (1) | ME00509B (is) |
| MX (1) | MXPA05003318A (is) |
| NO (1) | NO338309B1 (is) |
| NZ (1) | NZ538928A (is) |
| PL (1) | PL208073B1 (is) |
| RS (2) | RS52966B (is) |
| RU (1) | RU2333743C2 (is) |
| WO (1) | WO2004030650A2 (is) |
| ZA (1) | ZA200502150B (is) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080083187A (ko) * | 2006-01-05 | 2008-09-16 | 노바르티스아게 | 암 전이 및 암 전이와 관련된 골 소실의 예방 및 치료 방법 |
| US20070219811A1 (en) * | 2006-03-16 | 2007-09-20 | Kim John S | Method for using an internet-based CRM application to create an on-line leads marketplace |
| EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| EP2120859B1 (en) * | 2006-12-21 | 2013-11-20 | Stryker Corporation | Sustained-release formulations comprising bmp-7 crystals |
| US8318899B2 (en) | 2008-01-24 | 2012-11-27 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Lytic domain fusion constructs and methods of making and using same |
| JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| US8324347B2 (en) * | 2009-02-24 | 2012-12-04 | Institute For Systems Biology | Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry |
| TWI583391B (zh) * | 2009-05-01 | 2017-05-21 | 菲瑞茵國際中心股份有限公司 | 用於前列腺癌之治療的組成物 |
| TWI536999B (zh) | 2010-01-13 | 2016-06-11 | 艾普森藥品公司 | 製備持續釋放生長激素抑制素類似物之醫藥組成物之方法 |
| CN102204889B (zh) * | 2011-05-23 | 2013-09-18 | 蚌埠丰原涂山制药有限公司 | 一种醋酸地加瑞克冻干粉针剂及其制备方法 |
| ES3037194T1 (en) | 2012-06-01 | 2025-09-30 | Ferring Bv | Degarelix drug product |
| ITMI20121638A1 (it) * | 2012-10-02 | 2014-04-03 | Marco Sbracia | Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate |
| EP4035685A1 (en) | 2012-10-30 | 2022-08-03 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
| AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
| PL3576771T3 (pl) * | 2017-01-31 | 2022-08-16 | Veru Inc. | Kompozycje i sposoby długotrwałego uwalniania antagonistów gonadoliberyny (GnRH) |
| EP3639856B1 (en) | 2017-09-27 | 2022-08-03 | Novel Pharma Inc. | Long-acting palmitic acid-conjugated gnrh derivative and pharmaceutical composition containing same |
| KR102408886B1 (ko) * | 2018-01-31 | 2022-06-14 | 저장 산후아 클라이메이트 앤드 어플라이언스 컨트롤스 그룹 컴퍼니 리미티드 | 밸브 코어 조립체 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5411951A (en) * | 1984-10-04 | 1995-05-02 | Monsanto Company | Prolonged release of biologically active somatotropin |
| GB9108634D0 (en) * | 1991-04-23 | 1991-06-12 | Ciba Geigy | Pharmaceutical compositions |
| DE4305225A1 (de) * | 1993-02-19 | 1994-08-25 | Asta Medica Ag | Neues Herstellverfahren für Cetrorelix Lyophilisat |
| US6828415B2 (en) | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| DE4342091A1 (de) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5942493A (en) * | 1995-11-28 | 1999-08-24 | Asta Medica Aktiengesellschaft | LH-RH antagonists having improved action |
| US5916582A (en) * | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
| DE69737635T2 (de) * | 1996-08-30 | 2008-01-03 | Peptech Ltd., North Ryde | Formulierung zur verzögerten Freisetzung von Peptidagonisten und -analoga des GnRH |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| FR2776520B1 (fr) | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| EP1104296B1 (en) * | 1998-07-20 | 2012-06-13 | Peptech Animal Health Pty Limited | Bioimplant formulation |
| CO5160256A1 (es) * | 1999-02-08 | 2002-05-30 | Zentaris Ag | Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion |
| DE19911771B4 (de) | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| US7005418B1 (en) * | 1999-09-23 | 2006-02-28 | Zentaris Gmbh | Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction |
| US6635739B2 (en) | 1999-10-15 | 2003-10-21 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy |
| DE10024451A1 (de) * | 2000-05-18 | 2001-11-29 | Asta Medica Ag | Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung |
| GB0117057D0 (en) | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
-
2003
- 2003-09-26 US US10/529,203 patent/US7884071B2/en not_active Expired - Lifetime
- 2003-09-26 CA CA2507524A patent/CA2507524C/en not_active Expired - Lifetime
- 2003-09-26 ME MEP-2008-830A patent/ME00509B/me unknown
- 2003-09-26 KR KR1020057005291A patent/KR100633280B1/ko not_active Expired - Lifetime
- 2003-09-26 RU RU2005113163/15A patent/RU2333743C2/ru active
- 2003-09-26 BR BRPI0314546A patent/BRPI0314546B8/pt not_active IP Right Cessation
- 2003-09-26 RS RS20050247A patent/RS52966B/en unknown
- 2003-09-26 MX MXPA05003318A patent/MXPA05003318A/es active IP Right Grant
- 2003-09-26 PL PL376446A patent/PL208073B1/pl unknown
- 2003-09-26 AU AU2003287950A patent/AU2003287950B2/en not_active Expired
- 2003-09-26 WO PCT/EP2003/010732 patent/WO2004030650A2/de active Application Filing
- 2003-09-26 NZ NZ538928A patent/NZ538928A/en not_active IP Right Cessation
- 2003-09-26 ES ES03779793.3T patent/ES2457019T3/es not_active Expired - Lifetime
- 2003-09-26 JP JP2004540717A patent/JP4898118B2/ja not_active Expired - Lifetime
- 2003-09-26 EP EP03779793.3A patent/EP1565160B1/de not_active Expired - Lifetime
- 2003-09-26 HR HRP20050371AA patent/HRP20050371B1/hr not_active IP Right Cessation
- 2003-09-26 DK DK03779793.3T patent/DK1565160T3/da active
- 2003-09-26 RS YUP-2005/0247A patent/RS20050247A/sr unknown
- 2003-09-26 CN CNB038230003A patent/CN100509053C/zh not_active Expired - Lifetime
-
2005
- 2005-03-14 IL IL167415A patent/IL167415A/en active IP Right Grant
- 2005-03-15 ZA ZA2005/02150A patent/ZA200502150B/en unknown
- 2005-03-17 IS IS7750A patent/IS7750A/is unknown
- 2005-04-26 NO NO20052041A patent/NO338309B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7750A (is) | Inngjafarform fyrir lyfjafræðilega virk peptíð með samfellda losun og aðferð við framleiðslu þeirra | |
| NO2022041I1 (no) | Dapagliflozin og farmasøytisk akseptable salter derav - forlenget SPC | |
| LUC00127I1 (fr) | Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro ) | |
| IS2599B (is) | 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess | |
| IS7948A (is) | Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra | |
| NO2011021I1 (no) | Apixaban og farmasøytiske akseptable salter derav | |
| EP1477119A4 (en) | METHOD OF DRUG DELIVERY | |
| DK1673349T3 (da) | Benzimidazolderivater: fremstilling og farmaceutiske anvendelser | |
| NO2014005I1 (no) | olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav | |
| NO20050884L (no) | Ny fremgangsmate for syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre | |
| NO20031776L (no) | Null-boringskomplettering og produksjonssystem | |
| ATE524309T1 (de) | Verbundstrukturwerkstoff und herstellungsverfahren dafür | |
| DE60317887D1 (de) | System zur verabreichung therapeutischer substanzen | |
| AU2003287699A8 (en) | Production of pharmaceutically active proteins in sprouted seedlings | |
| EP1478345A4 (en) | NOVEL PHARMACEUTICAL DOSAGE FORMS AND PROCESS FOR PRODUCTION OF SAID DOSAGE FORMS | |
| EP1513825A4 (en) | ANTITU-CULINARY MEDICAMENT: COMPOSITIONS AND METHODS | |
| IS7699A (is) | Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma | |
| EP1575987A4 (en) | CONJUGATES OF MEMBRANE TRANSLOCATION AGENTS AND PHARMACEUTICAL ACTION AGENTS | |
| HUP0302050A3 (en) | Pharmaceutical form of administration for peptides, method for its production and use | |
| ATE451912T1 (de) | Arzneistoffhaltiger kaugummi, dessen herstellungsverfahren und so erhaltene tablette | |
| DE60321572D1 (de) | Transdermales arzneimittelverabreichungssystem | |
| PL359208A1 (en) | New derivatives of quinosoline, method of production of new derivatives of quinosoline and pharmaceutical preparations | |
| NO20042890L (no) | Farmasoytiske preparater og fremgangsmate for fremstilling derav | |
| AU2003230860A8 (en) | Method of self-assembly and self-assembled structures | |
| IS7846A (is) | Aðferð til að framleiða lyfjafræðilega virkt efnasamband og til að framleiða milliefni þess |